Download or read book Targeted cancer therapies from small molecules to antibodies volume II written by Zhe-Sheng Chen and published by Frontiers Media SA. This book was released on 2023-07-27 with total page 428 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Targeted Cancer Therapies From Small Molecules to Antibodies written by Zhe-Sheng Chen and published by Frontiers Media SA. This book was released on 2020-07-22 with total page 1123 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Multi targeted Natural Products as Cancer Therapeutics Challenges and Opportunities Volume I 2nd edition written by Jiang-Jiang Qin and published by Frontiers Media SA. This book was released on 2024-01-11 with total page 699 pages. Available in PDF, EPUB and Kindle. Book excerpt: This Research Topic is part of a series with: Multi-targeted Natural Products as Cancer Therapeutics: Challenges and Opportunities, Volume II Cancer remains a leading cause of disease-related deaths worldwide, despite recent advances in our understanding of cancer initiation, progression, and metastasis. Chemotherapy and radiotherapy have been used as standard non-surgical treatments of human cancer for decades, however, the survival rates of patients with cancer, especially those with advanced diseases are still very low due to the high toxicities of these treatments as well as the severe side effects. This fact has motivated researchers to discover new cancer therapeutics with minimum side effects, which intensively promotes the rapid development of single specific molecule-targeted therapies (SSMTT). Many efforts have been made in world-wide cancer drug discovery research and several single molecule-targeted therapies have been successfully developed. Unfortunately, most of the investments failed because cancer is a genetic disease and always harbors multiple alternations of molecules or genes at the genomic, genetic and epigenetic levels. The inhibition of a single molecule or signaling pathway by SSMTT frequently results in a hyperactive compensation of other cancer-related molecules and signaling pathways as well as the subsequent development of drug resistance. Therefore, identifying multi-targeted therapies, i.e. drugs that are able to target multiple cancer-related genes, proteins, or signaling pathways is a more promising way to success in developing new cancer therapeutics. Natural products, especially those from traditional Chinese medicine and folk remedies in other countries are an extraordinarily important source for new drug discovery over the past decades. Of note, many natural products have often been demonstrated to target several crucial genes or proteins in cancer-related signaling networks and exert synergistic effects. For example, Japonicone A, a dimeric sesquiterpenoid from the medicinal plant Inula japonica, has been found to inhibit tumor growth and metastasis by dually targeting the TNF-α/NF-κB and p53/MDM2 signaling pathways. Traditionally, researchers have believed that the multi-targeting mechanisms of natural products have limited their use in cancer treatment due to the low specificity and potential side effects. The growing interest in developing multi-targeted cancer therapies may provide another golden opportunity to develop natural products as new cancer therapeutics. Nevertheless, critical investigations for a comprehensive understanding of the molecular mechanisms of natural products also mean more challenges. Our long-term goals are to fully understand the molecular targets and mechanisms of action of anticancer natural products and develop them as novel cancer preventive and therapeutic agents. The specific goal of this Research Topic is to bring together the recent findings of newly identified anticancer natural products, especially those with multiple molecular targets. Papers (Original Research articles or Reviews) which discuss the in vitro and in vivo efficacy and pharmacological and toxicological properties of natural products are also welcome to be submitted. Guidelines for the conception and review of submissions As many anticancer drugs working as cytotoxic compounds have non-selective effects annihilating their potential therapeutic benefits, manuscripts are advised to provide evidence of a significant selectivity towards cancer cells (vs. healthy cells). Specifically, if the studied anticancer drug or modality does not target an oncogenic pathway, the authors should make every effort possible to prove that the cytotoxic or cytostatic effects they have identified exhibit selectivity for cancer cells (ideally 1 log difference in EC50 or IC50) vs. non-malignant cells (eg, fibroblasts or primary culture of cells). The authors should also demonstrate the applicability of their anticancer modalities on a minimum of two well-authenticated cancer cell lines (ideally originating from distinct organs/tissues). For manuscripts dealing with plant extracts or other natural substances/compounds, the composition and the stability of the study material must be described in sufficient detail. In particular, for extracts, chromatograms with characterization of the dominating compound(s) are requested. The level of purity must be proven and included. Please refer to the Four Pillars of Best Practice in Ethnopharmacology, a subset of which concerning general standards in natural product research are applied to all such studies in all sections of Frontiers in Pharmacology.
Download or read book Small Molecules in Oncology written by Uwe M. Martens and published by Springer Science & Business Media. This book was released on 2010-01-14 with total page 242 pages. Available in PDF, EPUB and Kindle. Book excerpt: Extensive research into the molecular mechanisms of cancer disease has heralded a new age of targeted therapy. In malignant cells, key proteins that are crucial to tumor growth and survival are now being targeted directly with rationally designed inhibitors. Apart from monoclonal antibodies, small molecule therapeutics such as oncogenic protein kinase inhibitors are attracting a vast amount of investigational attention. This textbook, written by acknowledged experts, provides a broad overview of the small molecules currently used for the treatment of malignant diseases and discusses interesting novel compounds that are in the process of clinical development to combat cancer.
Download or read book Advances in Targeted Cancer Therapy written by Richard M. Schultz and published by Springer Science & Business Media. This book was released on 2006-01-24 with total page 294 pages. Available in PDF, EPUB and Kindle. Book excerpt: There have been tremendous advances in our understanding of molecular and tumor biology during the past few years. In the field of cancer therapeutics, it is expected that cytotoxic drug approaches will be gradually replaced with treatments based on biological targeted approaches. Hopefully these new targeted therapies will significantly increase efficacy and lack the devastating and troublesome side effects elicited by cytotoxic chemotherapy. This volume is the first book to cover the general topic of targeted cancer therapy. It presents a range of targets such as tumor angiogenesis, cell cycle control and cell signalling, COX-2, apoptosis/cell survival, invasion and metastasis and approaches like kinase inhibitors, antisense, and antibody-based therapeutics. The emphasis is on preclinical development, including target validation, development of biomarkers, strategies for combination approaches, and development of resistance. The particular challenges involved in translating these data to clinical application are discussed. This volume should be of broad general interest to researchers and clinicians involved in cancer therapy as well as other scientists interested in current strategies for cancer treatment.
Download or read book Safety of Biologics Therapy written by Brian A. Baldo and published by Springer. This book was released on 2016-08-12 with total page 623 pages. Available in PDF, EPUB and Kindle. Book excerpt: This long overdue title provides a comprehensive, up-to-date, state-of-the art review of approved biologic therapies, with coverage of mechanisms of action, Indications for therapy, immunogenicity and a detailed examination of adverse effects and safety of the many and diverse therapeutic agents presented in a total of 13 chapters. It is predicted that by 2016, biologics will make up half of the world's 20 top-selling drugs and by 2018, biologic medicine sales will account for almost half of the world's 100 biggest selling drugs. Recombinant proteins dominate the growing list of the more than 200 approved biotherapeutic agents with targeted antibodies, fusion proteins and receptors; cytokines; hormones; enzymes; proteins involved in blood-clotting, homeostasis and thrombosis; vaccines; botulinum neurotoxins; and, more recently, biosimilar preparations, comprising the majority of approved biologics. Written with clinicians, other health care professionals, and researchers in mind, Safety of Biologics Therapy examines, in a single volume, the full range of issues surrounding the safety of approved biologic therapies. A good understanding of the risks and safety issues of modern biologics therapy is increasingly being demanded of all those connected with their development, handling, prescribing, administration and subsequent patient management. In addition to being of great value to clinicians in all branches of medicine, and to nurses, pharmacists and researchers, this book will prove invaluable for students taking undergraduate and graduate courses in the above disciplines and in the biomedical sciences.
Download or read book Introduction to Biological and Small Molecule Drug Research and Development written by null Hasmann and published by Elsevier Inc. Chapters. This book was released on 2013-05-07 with total page 33 pages. Available in PDF, EPUB and Kindle. Book excerpt: HER2 (ErbB-2) is a member of the human epidermal growth factor receptor tyrosine kinase family which is involved in the regulation of cell proliferation, survival and differentiation. Soon after its discovery, HER2 was shown frequently to be overexpressed in breast cancer and was associated with a worse prognosis. It was identified as a target for drug development and molecular cloning of the gene and expression in cell lines provided a vehicle for the selection of HER2-specific antibodies. The monoclonal antibody trastuzumab is the first HER2-targeting drug approved for cancer treatment. By significantly extending the time to disease progression and overall survival of patients, it has become established in all treatment lines of early and metastatic HER2-positive breast cancer, as well as in HER2-positive advanced metastatic gastric or gastroesophageal junction cancer. Combination of trastuzumab with pertuzumab, a second antibody binding to a distinct epitope on HER2 which implies a different mode of action, took the treatment of HER2-positive metastatic breast cancer to the next level of success. Finally, trastuzumab emtansine is an antibodydrug conjugate that retains all pharmacodynamic activities of trastuzumab and delivers a toxic maytansinoid directly to the tumour cells. Current clinical results indicate that trastuzumab emtansine may be more efficacious and less toxic than trastuzumab plus chemotherapy, and further improvement is expected in combination with pertuzumab.
Download or read book Targeted Radionuclide Therapy written by Tod W. Speer and published by Lippincott Williams & Wilkins. This book was released on 2012-03-28 with total page 564 pages. Available in PDF, EPUB and Kindle. Book excerpt: Radioimmunotherapy, also known as systemic targeted radiation therapy, uses antibodies, antibody fragments, or compounds as carriers to guide radiation to the targets. It is a topic rapidly increasing in importance and success in treatment of cancer patients. This book represents a comprehensive amalgamation of the radiation physics, chemistry, radiobiology, tumor models, and clinical data for targeted radionuclide therapy. It outlines the current challenges and provides a glimpse at future directions. With significant advances in cell biology and molecular engineering, many targeting constructs are now available that will safely deliver these highly cytotoxic radionuclides in a targeted fashion. A companion website includes the full text and an image bank.
Download or read book Targeted Cancer Therapy written by Razelle Kurzrock and published by Springer Science & Business Media. This book was released on 2008-03-07 with total page 447 pages. Available in PDF, EPUB and Kindle. Book excerpt: Emerging technologies in target identification, drug discovery, molecular markers, and imaging are rapidly changing the face of cancer. This book provides a foundation of knowledge in targeted cancer therapeutics. The treatment of cancer is increasingly being individualized, based on an understanding of underlying biologic mechanisms. Poised to change the landscape in oncology, this volume provides a state-of-the-art overview. It will be valuable to practicing and academic physicians, fellows, residents and students, as well as basic scientists, interested in the cancer field.
Download or read book Targeted Drug Strategies for Cancer and Inflammation written by Ann L. Jackman and published by Springer Science & Business Media. This book was released on 2011-05-05 with total page 262 pages. Available in PDF, EPUB and Kindle. Book excerpt: Folate pathways are essential in metabolism and macromolecule synthesis. Antifolate drugs that are largely transported via a high capacity folate transporter (i.e. the reduced-folate carrier) and inhibit folate-dependent enzymes include the dihydrofolate reductase inhibitor, methotrexate, and the thymidylate synthase inhibitors, raltitrexed and pemetrexed. Major advances in folate research made within the last decade include (i) the approval of pemetrexed for the treatment of lung cancer and mesothelioma, and (ii) the demonstration that cell membrane-anchored folate receptors (FR) are exploitable for cancer and inflammatory disease management. FRs are not widely distributed in normal tissues, except on some luminal surfaces; however, they are accessible to systemically administered agents when expressed on many cancers as well as on activated macrophages involved in various inflammatory diseases. High affinity folate-radioisotope conjugates have been developed for imaging pathogenic FR-positive diseases, including cancer. Since the FR transports folates via a low capacity but high affinity endocytic pathway, a variety of FR-targeted antifolate drugs and folate conjugates bearing a wide range of payloads (including cytotoxic drugs) are currently being developed which exploit this property. The FR is also being utilized in immunotherapy approaches for the treatment of overexpressing cancers.
Download or read book Small Molecules in Hematology written by Uwe M. Martens and published by Springer. This book was released on 2018-08-01 with total page 297 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book, written by respected experts, discusses in detail the latest developments in targeted therapy for hematologic malignancies using small molecules. It covers a wide range of small molecules including tyrosine kinase inhibitors, immunomodulatory drugs, the IDH-2 inhibitor enasidenib, the BCL-2 inhibitor venetoclax, and the proteasome inhibitor carfilzomib. For each molecule, aspects such as the chemical structure, mechanism of action, drug targets, drug interactions, preclinical studies, clinical trials, treatment applications, and toxicity are discussed. Extensive research into the molecular mechanisms of cancer has heralded a new age of targeted therapy. The field of precision cancer therapy is now growing rapidly, and the advances being made will mean significant changes in the treatment algorithms for cancer patients. Numerous novel targets that are crucial for the survival of cancer cells can be attacked by small molecules such as protein tyrosine kinase inhibitors. An accompanying volume addresses the use of small molecules in oncology, and the two volumes together represent the third edition of the book originally published under the same title.
Download or read book Apoptosis and Cancer Chemotherapy written by John A. Hickman and published by Springer Science & Business Media. This book was released on 1999-04-08 with total page 347 pages. Available in PDF, EPUB and Kindle. Book excerpt: The past few years have witnessed an astonishing international effort that established the role of some 20 new molecules in apoptosis and added activation or suppression of apoptosis to the accepted biological functions of a great many others already familiar in cancer biology. Some of these molecules are receptors, transducing cytokine-mediated signals; others appear to intensify or diminish the risk that a compro mised cell will fire its apoptosis effector mechanism. All are of interest as potential targets for tumor therapy, and some may prove to be control points influenced in the pathogenesis of cancer and other diseases as diverse as viral infection, neurodegenerative disorders, and stroke. Sometimes, in the midst of these developments, a kind of euphoria ap pears to have gripped the research community, with the expectation that apoptosis will afford explanations to many unsolved questions in cellu lar regulation. This book, in a series of thoughtful and provocative ar ticles--some from established leaders in the field, and others from younger scientists--seeks to redress the balance.
Download or read book Targeted Therapies in Breast Cancer written by Gw Sledge and published by Clinical Pub. This book was released on 2012-06 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: This new volume updates the reader on selected areas of targeted therapy in breast cancer, with special emphasis on chemoprevention strategies, drug resistance, biomarkers, combination chemotherapy, angiogenesis inhibition and pharmacogenomics in the context of clinical efficacy. This selected review of targeted therapies will guide the reader on effective treatment as part of an integrated programme of patient management.
Download or read book Macromolecular Anticancer Therapeutics written by L. Harivardhan Reddy and published by Springer Science & Business Media. This book was released on 2010-03-20 with total page 627 pages. Available in PDF, EPUB and Kindle. Book excerpt: In spite of the development of various anticancer drugs, the therapy of cancer has remained challenging for decades. The current therapy of cancer is overwhelmed because of the inability to deliver therapeutics to all regions of a tumor in effective therapeutic concentrations, intrinsic or acquired resistance to the treatment with currently available agents via genetic and epigenetic mechanisms, and toxicity. As a result, cancer therapy using conventional therapeutics and different types of treatment regimens using this therapeutics has not led to a convincing survival benefit of the patients. In this context, Macromolecular therapeutics offer several advantages over conventional low molecular therapeutics by various ways such as, enable the use of larger doses of these agents by limiting the toxicity, by enhanced permeability and retention into tumors, by tumor targeting using tumor-specific antibodies, by specific inhibition of oncogenes using anticancer oligonucleotides etc. Cancer treatment using this macromolecular therapeutics has considerably improved the survival benefit for patients. As a result, various macromolecular therapeutics are already commercialized or are under clinical development. Although we are far from a real magic bullet today, looking at the pace of research and current success in this field of macromolecular therapeutics, it appears that we are approaching a magic bullet for the efficient treatment of cancer. Thus, we believe that the subject of this book is very timely, and that the book will fill an unmet need in the market. This book is unique and assembles various types and aspects of macromolecular anticancer therapeutics for cancer therapy in one shell and conveys the importance of this interdisciplinary field to the broad audience. Thus, in a nutshell, this book details the basics of cancer, and various therapeutic strategies such as those based on macromolecular therapeutics hence can become an important reference for practitioners, oncologists, medical pharmacologists, medicinal chemists, biomedical scientists, experimental pharmacologists, pharmaceutical technologists, and particularly it can essentially become a handbook of macromolecular therapeutics for cancer therapy for graduates, post-graduates and Ph.D. students in these fields.
Download or read book Hepatocellular Carcinoma written by Yujin Hoshida and published by Springer. This book was released on 2019-08-05 with total page 366 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book provides a comprehensive overview of the current limitations and unmet needs in Hepatocellular Carcinoma (HCC) diagnosis, treatment, and prevention. It also provides newly emerging concepts, approaches, and technologies to address challenges. Topics covered include changing landscape of HCC etiologies in association with health disparities, framework of clinical management algorithm, new and experimental modalities of HCC diagnosis and prognostication, multidisciplinary treatment options including rapidly evolving molecular targeted therapies and immune therapies, multi-omics molecular characterization, and clinically relevant experimental models. The book is intended to assist collaboration between the diverse disciplines and facilitate forward and reverse translation between basic and clinical research by providing a comprehensive overview of relevant areas, covering epidemiological trend and population-level patient management strategies, new diagnostic and prognostic tools, recent advances in the standard care and novel therapeutic approaches, and new concepts in pathogenesis and experimental approaches and tools, by experts and opinion leaders in their respective fields. By thoroughly and concisely covering whole aspects of HCC care, Hepatocellular Carcinoma serves as a valuable reference for multidisciplinary readers, and promotes the development of personalized precision care strategies that lead to substantial improvement of disease burden and patient prognosis in HCC.
Download or read book Targeted Therapies in Cancer written by Manfred Dietel and published by Springer. This book was released on 2014-11-23 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: From its introduction, oncological chemotherapy has been encumbered by poor selectivity because antiproliferative drugs are often toxic not only to tumor cells but also to important populations of the body’s non-neoplastic cells. Modern targeted therapies interact with defined molecules present on cancer cells, adding increased selectivity to their toxic effects. This book presents an integrated critical view on the theories, mechanisms, problems and pitfalls of the targeted therapy approach.
Download or read book Oncology Targeted Therapies for Tumors written by Adelina Brando and published by American Medical Publishers. This book was released on 2023-09-26 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: Tumor, also known as neoplasm, is a mass or group of tissues that is formed as a result of abnormal growth. It can appear anywhere on the body. Bone, tissues, skin, glands, and organs, all can be affected by tumors. They may be cancerous (malignant), non-cancerous (benign), or precancerous. Malignant tumors can spread to adjacent tissues, glands, or other body parts. Benign tumors pose a low risk of death. They are isolated and do not spread to other body parts or impact neighboring tissues. Precancerous tumors are non-cancerous tumors which may become cancerous if left untreated. Most common types of cancer treatments include targeted therapy (molecularly targeted therapy), hormonal therapy and cytotoxic therapy. There exist two types of targeted therapies, namely, small molecule medicines and monoclonal antibodies. The small molecule medicines are biopharmaceuticals that are so small that they can enter the cancer cells and destroy them. Targeted therapy makes use of monoclonal antibodies which cannot enter into the cells. However, these monoclonal antibodies attack targets outside of cells. In various cases, monoclonal antibodies are used to launch chemo and radiation straight into tumors. This book aims to provide the readers a comprehensive overview of the applications of targeted therapies for the treatment and management of tumors. For all readers who are interested in understanding this therapeutic procedure, it will serve as an excellent guide.
